Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15660263 | 0.85 | EPHX2 (0.74) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL17645838 | 0.83 | EPHX2 (0.59) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL29008902 | 0.82 | EPHX2 (0.70) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL26107231 | 0.79 | HDAC3 (0.80) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL20840178 | 0.78 | NPC1 (0.48) | EPHX2RAB9AMEN1KMT2ACYP1A2 | |
| SCHEMBL16793744 | 0.77 | KLKB1 (0.50) | EPHX2BTKLMNA | |
| SCHEMBL540605 | 0.76 | SETDB1 (0.57) | EPHX2HDAC6RAB9AMEN1KMT2A | |
| SCHEMBL25245236 | 0.76 | BTK (0.51) | EPHX2BTKRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL17645859 | 0.76 | EPHX2 (0.62) | EPHX2NR1H4BTKLMNARAB9A | |
| SCHEMBL20365215 | 0.76 | EPHX2 (0.76) | EPHX2NR1H4HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212999-A | Pyrrolopyrimidine compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-12-27 | — | — | CN | disclosed |
| CN-117164591-A | Pyrrolopyrimidine compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023226580-A1 | PYRROLOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 中国医学科学院药物研究所 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023183652-A1 | DUAL CXCR4-BTK INHIBITORS | X4 PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183652-A1 | DUAL CXCR4-BTK INHIBITORS | X4 PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-115417827-B | 6-amino-1, 3, 5-triazine compound and synthetic method and application thereof | 中国药科大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-115417827-A | 6-amino-1, 3, 5-triazine compound and synthesis method and application thereof | 中国药科大学 | 2022-12-02 | — | — | CN | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | EPHX2 1940/4885NR1H4 3566/4885HDAC3 1259/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | EPHX2 2154/4885NR1H4 3942/4885HDAC3 1658/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | EPHX2 1940/4885NR1H4 3566/4885HDAC3 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.